NCT05813496 - Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt | Biotech Hunter

Enrollment

430

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

August 3, 2024

Study Completion Date

December 11, 2024

Conditions

Polyneuropathy, Diabetic

Interventions

DRUG

Alpha-Lipoic Acid (ALA)

Oral tablet

DRUG

Placebo

Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.

Trial Locations (5)

11588

Ain-Shams University Hospital, Cairo

21544

Alexandria University, Alexandria

2711860

Beni Suef University Hospital, Banī Suwayf

Unknown

Menoufia University Hospital, Shibīn al Kawm

Mansoura University Hospital, Al Mansurah